Cytokinetics (CYTK) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.37

Estimate

-$1.41

Surprise

+2.6%

Revenue (period 2026-09-30)

$47.6M

Score today

5.0/10

Revenue source: xbrl.

Cytokinetics (CYTK) reported a narrower loss than forecast — adjusted EPS of -$1.37 against the -$1.41 estimate (a 2.6% beat on a still-unprofitable quarter).

• RBC Capital Markets Comments on Cytokinetics' Myqorzo Revenue Potential — fiscal.ai, 2026-11-05
• Leerink Partners Maintains Cytokinetics at Outperform, Lowers Price Target — fiscal.ai, 2026-11-05
• Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 — benzinga, 2026-11-05

TrendMatrix currently rates CYTK Sell at 5.0/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +2.6% surprise compares with a -0.5% four-quarter average. Next scheduled report: 2027-02-24.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$55.01

Price target

$96.65

Stop

$52.54

Upside to target

+75.7%

Reward-to-risk

7.9:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$7.72B

P/E (fwd)

-12.6

52-week range

$54.16–$88.31

Off 52-week high

37.7%

RSI (14)

30

Volume vs avg

0.44×

Score today

5.0/10